What is the appropriate ACE (Angiotensin-Converting Enzyme) inhibitor and dosing regimen for an 18kg pediatric patient with heart failure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 7, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

ACE Inhibitor Selection and Dosing for an 18kg Pediatric Patient with Heart Failure

For an 18kg child with heart failure, start with enalapril 0.1 mg/kg/day (1.8mg) once daily or divided twice daily, titrating up to a target of 0.5 mg/kg/day (9mg daily) as tolerated. 1

Why Enalapril is the Preferred Choice

  • Enalapril is the most widely studied and used ACE inhibitor in pediatric heart failure, with established safety and efficacy data in children 1
  • Enalapril can be administered once or twice daily, improving adherence compared to captopril's three-times-daily dosing 1
  • For this 18kg patient, the practical dosing is straightforward: start at approximately 2mg once daily (rounding from 1.8mg for ease of administration) 1

Specific Dosing Protocol for This Patient

Initial dose:

  • Start with 0.1 mg/kg/day = 1.8-2mg once daily (can divide into twice daily if preferred) 1

Titration schedule:

  • Increase dose every 2 weeks minimum if tolerated 2
  • Double the dose at each titration step 2
  • Target dose: 0.5 mg/kg/day = 9mg daily (can be given once or divided twice daily) 1

Maximum dose considerations:

  • Pediatric studies have used up to 0.5 mg/kg/day safely 1
  • The absolute maximum would be 9mg daily for this weight, though some protocols allow higher in older children 3

Alternative: Captopril (Second-Line Choice)

If enalapril is unavailable or not tolerated:

  • Starting dose: 0.3 mg/kg/day = 5.4mg daily divided into three doses (approximately 2mg three times daily) 1
  • Target dose: Up to 1.5 mg/kg/day = 27mg daily divided three times daily 1
  • The three-times-daily dosing makes this less practical than enalapril 1

Critical Monitoring Requirements

Before starting:

  • Baseline blood pressure, renal function (creatinine), and potassium 2
  • Assess for volume depletion and optimize diuretic dose first 4

Within 1-2 weeks of initiation and after each dose increase:

  • Blood pressure (watch for symptomatic hypotension) 2
  • Serum creatinine (up to 50% increase from baseline is acceptable) 2
  • Serum potassium (keep <5.0 mEq/L) 2

Ongoing:

  • Monitor at least every 2 weeks during titration 2
  • Continue monitoring every 1-2 months once at target dose 2

Common Pitfalls and How to Avoid Them

Hypotension within first 5 days:

  • Most common early complication in pediatrics 1
  • Usually resolves with dose reduction or temporary cessation 1
  • Reduce diuretic dose first if no signs of congestion 2
  • Do not stop ACE inhibitor unless hypotension is severe or prolonged 2

Renal dysfunction:

  • Expect small increases in creatinine—this is acceptable 2
  • Creatinine increases up to 50% above baseline are tolerable 2
  • If creatinine rises more than 50%, halve the ACE inhibitor dose and recheck 2
  • Stop nephrotoxic drugs (NSAIDs) if available 2

Hyperkalemia:

  • Avoid potassium supplements and potassium-sparing diuretics when possible 2
  • If potassium rises above 5.5 mEq/L, reduce ACE inhibitor dose 2

Administration Pearls

  • Start low, go slow: Begin with the lowest dose to prevent first-dose hypotension 1
  • Some ACE inhibitor is better than none: If target dose cannot be reached, use the highest tolerated dose 2
  • Never stop abruptly: Sudden discontinuation can cause clinical deterioration 2, 5
  • Combine with other heart failure medications: ACE inhibitors work best alongside diuretics, and often digoxin or beta-blockers 1

When to Seek Specialist Consultation

  • Baseline creatinine >2.5 mg/dL 2
  • Baseline potassium >5.0 mEq/L 2
  • Systolic blood pressure <90 mmHg 2
  • Persistent hypotension or renal dysfunction despite dose adjustments 2
  • Any consideration of stopping the ACE inhibitor 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

ACE Inhibitor Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the initial management for a patient with class II heart failure taking an Angiotensin-Converting Enzyme (ACE) inhibitor who reports a recurring cough that interferes with sleep?
What medication should be added to a patient with controlled and asymptomatic Heart Failure (HF) who is already on Angiotensin-Converting Enzyme Inhibitor (ACEI), furosemide, and simvastatin?
What is the role of Angiotensin-Converting Enzyme (ACE) inhibitors and beta blockers in the treatment of congestive heart failure?
What is the next step in managing a patient with heart failure and reduced ejection fraction who is already on optimal medical therapy including ACE inhibitors or ARBs, beta-blockers, and high-intensity statins?
What is the optimal management plan for a patient with a recent hospitalization for congestive heart failure (CHF), ongoing symptoms, and impaired ejection fraction, who is currently on an Angiotensin-Converting Enzyme (ACE) inhibitor and a beta blocker, and following a low-sodium diet?
What's the next step in managing a patient with heart failure and a parasitic infection who improved with Furosemide (Lasix) intravenous (IV) therapy?
What is the recommended treatment approach for a patient with panic disorder and a history of substance abuse who has not responded to buspirone (Buspar) treatment, when considering starting escitalopram (Lexapro) and clonazepam (Klonopin)?
What is the recommended management of statin (HMG-CoA reductase inhibitor) therapy in patients with a history of intracerebral hemorrhage, particularly those with hypertension and high cardiovascular risk?
What is the pharmacology of Rocuronium (a non-depolarizing neuromuscular blocking agent) in patients with impaired renal or hepatic function?
What is the protocol for continuous platelet transfusion in a patient requiring ongoing transfusions to manage thrombocytopenia?
What is the next best step for a patient with a history of ineffective buspirone treatment for panic attacks, considering initiation of escitalopram (selective serotonin reuptake inhibitor) and clonazepam (benzodiazepine)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.